drugset / Trial / NCT04192903
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate therapeutic efficacy and safety of Chidamide combined with Cisplatin for relapsed or metastatic triple-negative breast cancer.
Timeline
- Start
- 2019-12-25
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |